{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T14:10:10Z","timestamp":1748441410290,"version":"3.41.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100022308","name":"Karl Landsteiner Privatuniversit\u00e4t f\u00fcr Gesundheitswissenschaften","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022308","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Consolidation immunotherapy with immune checkpoint Inhibitor (ICI) Durvalumab is an effective treatment for inoperable stage\u00a0III non-small cell lung cancer (NSCLC) patients with a\u00a0PD-L1 expression \u2265\u202f1% after definitive curative concurrent chemoradiotherapy (CCRT). While this approach is widely used as standard therapy, it carries an increased risk of immune-related and radiation-induced pneumonitis. Currently, there is no data on pneumonitis in <jats:italic>patients receiving CCRT with an overall dose of 70<\/jats:italic>\u202f<jats:italic>Gy (Gy) compared with the standard<\/jats:italic> protocol of 60\u202fGy\u202f\u00b1\u200910% in this setting.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This study analyzed retrospective data from 39\u00a0patients with unresectable NSCLC treated with CCRT. Patients received either 70\u202fGy (<jats:italic>n<\/jats:italic>\u202f=\u200929) or lower than 70\u202fGy total dose (<jats:italic>n<\/jats:italic>\u202f=\u200910) in 2\u202fGy fractions. Cases of pneumonitis were further classified as RI\u2011P (Radio-induced Pneumonitis) and ICI\u2011P (ICI Pneumonitis) based on clinical and radiological findings.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Of the 39\u00a0patients, 15\u00a0(38.5%) developed pneumonitis, with 10\u00a0out of 29\u00a0(34.5%) in the 70\u202fGy\u00a0group\u00a0and five out 10\u00a0(50%) in the &lt;\u202f70\u202fGy\u00a0group. There was no significant difference in pneumonitis and in occurrence of ICI\u2011P vs. RI\u2011P (26.7% vs. 73.3%) within both groups. The 70\u202fGy\u00a0group\u00a0showed a\u00a0significant benefit in mortality (<jats:italic>p<\/jats:italic>\u202f=\u2009&lt;\u202f0.001). Overall survival (OS) differed significantly between groups (<jats:italic>p<\/jats:italic>\u202f=0.028).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>70\u202fGy radiation dose for CCRT followed by durvalumab is a\u00a0safe regimen and may provide clinical benefits in NSCLC patients compared to lower doses. Pneumonitis incidence aligns with previous literature. The higher dose is associated with improved overall survival, and reduced disease progression, potentially due to a\u00a0longer consolidation time.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00066-025-02369-0","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T13:56:15Z","timestamp":1739454975000},"page":"656-665","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["High radiation dose in chemoradiotherapy followed by immunotherapy with durvalumab in patients with stage\u00a0III non-small cell lung cancer does not increase risk for pneumonitis"],"prefix":"10.1007","volume":"201","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7019-8325","authenticated-orcid":false,"given":"Felix","family":"Schragel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Matousek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Resl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gudrun","family":"Kreye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nguyen-Son","family":"Le","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Errhalt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Georg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Hackner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,13]]},"reference":[{"issue":"20","key":"2369_CR1","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia\u00a0SJ et\u00a0al (2017) Durvalumab after chemoradiotherapy in stage\u00a0III non-small-cell lung cancer. N\u00a0Engl J Med 377(20):1919\u20131929","journal-title":"N Engl J Med"},{"issue":"11","key":"2369_CR2","doi-asserted-by":"publisher","first-page":"6690","DOI":"10.21037\/jtd-20-1792","volume":"12","author":"C Hassanzadeh","year":"2020","unstructured":"Hassanzadeh\u00a0C et\u00a0al (2020) Implications of pneumonitis after chemoradiation and durvalumab for locally advanced non-small cell lung cancer. J\u00a0Thorac Dis 12(11):6690\u20136700","journal-title":"J Thorac Dis"},{"issue":"2","key":"2369_CR3","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.jtho.2018.09.021","volume":"14","author":"SE Schild","year":"2019","unstructured":"Schild\u00a0SE et\u00a0al (2019) Toxicity related to radiotherapy dose and targeting strategy: a\u00a0pooled analysis of cooperative group trials of combined modality therapy for locally advanced non-small cell lung cancer. J\u00a0Thorac Oncol 14(2):298\u2013303","journal-title":"J Thorac Oncol"},{"key":"2369_CR4","first-page":"54","volume":"29","author":"Y Oshiro","year":"2021","unstructured":"Oshiro\u00a0Y et\u00a0al (2021) Risk factor of pneumonitis on dose-volume relationship for chemoradiotherapy with durvalumab: Multi-institutional research in Japan. Clin Transl Radiat Oncol 29:54\u201359","journal-title":"Clin Transl Radiat Oncol"},{"issue":"Suppl\u00a021","key":"2369_CR5","doi-asserted-by":"publisher","first-page":"S2465","DOI":"10.21037\/jtd.2018.01.153","volume":"10","author":"MC Roach","year":"2018","unstructured":"Roach\u00a0MC, Bradley\u00a0JD, Robinson\u00a0CG (2018) Optimizing radiation dose and fractionation for the definitive treatment of locally advanced non-small cell lung cancer. J\u00a0Thorac Dis 10(Suppl\u00a021):S2465","journal-title":"J Thorac Dis"},{"issue":"2","key":"2369_CR6","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S1470-2045(14)71207-0","volume":"16","author":"JD Bradley","year":"2015","unstructured":"Bradley\u00a0JD et\u00a0al (2015) Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a\u00a0randomised, two-by-two factorial phase\u00a03\u00a0study. Lancet Oncol 16(2):187\u2013199","journal-title":"Lancet Oncol"},{"issue":"1","key":"2369_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13014-021-01979-z","volume":"17","author":"H Mayahara","year":"2022","unstructured":"Mayahara\u00a0H et\u00a0al (2022) Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer. Radiat Oncol 17(1):7","journal-title":"Radiat Oncol"},{"issue":"10","key":"2369_CR8","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1093\/annonc\/mdw276","volume":"27","author":"J Brower","year":"2016","unstructured":"Brower\u00a0J et\u00a0al (2016) Improved survival with dose-escalated radiotherapy in stage\u00a0III non-small-cell lung cancer: analysis of the National Cancer Database. Ann Oncol 27(10):1887\u20131894","journal-title":"Ann Oncol"},{"issue":"8","key":"2369_CR9","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1001\/jamaoncol.2024.1841","volume":"10","author":"SG Chun","year":"2024","unstructured":"Chun\u00a0SG et\u00a0al (2024) Long-term prospective outcomes of intensity modulated radiotherapy for locally advanced lung cancer: a\u00a0secondary analysis of a\u00a0randomized clinical trial. JAMA Oncol 10(8):1111\u20131115","journal-title":"JAMA Oncol"},{"issue":"5","key":"2369_CR10","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1111\/1759-7714.13394","volume":"11","author":"Y Miura","year":"2020","unstructured":"Miura\u00a0Y et\u00a0al (2020) Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non-small cell lung cancer: management of adverse events. Thorac Cancer 11(5):1280\u20131287","journal-title":"Thorac Cancer"},{"issue":"10","key":"2369_CR11","doi-asserted-by":"publisher","first-page":"e1822","DOI":"10.1002\/onco.13900","volume":"26","author":"X Chen","year":"2021","unstructured":"Chen\u00a0X et\u00a0al (2021) Radiation versus immune checkpoint inhibitor associated pneumonitis: distinct radiologic morphologies. The Oncol 26(10):e1822\u2013e1832","journal-title":"The Oncol"},{"issue":"12","key":"2369_CR12","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1016\/j.jtho.2018.08.2035","volume":"13","author":"K Suresh","year":"2018","unstructured":"Suresh\u00a0K et\u00a0al (2018) Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors. J\u00a0Thorac Oncol 13(12):1930\u20131939","journal-title":"J Thorac Oncol"},{"issue":"8","key":"2369_CR13","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.jtho.2020.04.002","volume":"15","author":"Y Suzuki","year":"2020","unstructured":"Suzuki\u00a0Y et\u00a0al (2020) Assessment of immune-related interstitial lung disease in patients with NSCLC treated with immune checkpoint inhibitors: a\u00a0multicenter prospective study. J\u00a0Thorac Oncol 15(8):1317\u20131327","journal-title":"J Thorac Oncol"},{"key":"2369_CR14","first-page":"123","volume":"12","author":"O Fitzpatrick","year":"2021","unstructured":"Fitzpatrick\u00a0O, Naidoo\u00a0J (2021) Immunotherapy for stage\u00a0III NSCLC: durvalumab and beyond. Cancer Treat Res 12:123\u2013131","journal-title":"Cancer Treat Res"},{"issue":"5","key":"2369_CR15","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.cllc.2021.01.017","volume":"22","author":"T Shintani","year":"2021","unstructured":"Shintani\u00a0T et\u00a0al (2021) Incidence and risk factors of symptomatic radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent chemoradiotherapy and consolidation durvalumab. Clin Lung Cancer 22(5):401\u2013410","journal-title":"Clin Lung Cancer"},{"key":"2369_CR16","first-page":"174","volume":"174","author":"Y Kuang","year":"2022","unstructured":"Kuang\u00a0Y et\u00a0al (2022) Chemoradiation-induced pneumonitis in patients with unresectable stage\u00a0III non-small cell lung cancer: a\u00a0systematic literature review and meta-analysis. Cancer Treat Res 174:174\u2013185","journal-title":"Cancer Treat Res"},{"issue":"2","key":"2369_CR17","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/0360-3016(94)00477-3","volume":"31","author":"GW Morgan","year":"1995","unstructured":"Morgan\u00a0GW, Pharm\u00a0B, Breit\u00a0SN (1995) Radiation and the lung: a\u00a0reevaluation of the mechanisms mediating pulmonary injury. Int J Radiat Oncol Biol Phys 31(2):361\u2013369","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"12","key":"2369_CR18","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1200\/JCO.21.01308","volume":"40","author":"DR Spigel","year":"2022","unstructured":"Spigel\u00a0DR et\u00a0al (2022) Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage\u00a0III non\u2013small-cell lung cancer. JCO 40(12):1301","journal-title":"JCO"},{"key":"2369_CR19","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ejca.2020.10.008","volume":"142","author":"A Desilets","year":"2021","unstructured":"Desilets\u00a0A et\u00a0al (2021) Durvalumab therapy following chemoradiation compared with a\u00a0historical cohort treated with chemoradiation alone in patients with stage\u00a0III non-small cell lung cancer: A\u00a0real-world multicentre study. Eur J Cancer 142:83\u201391","journal-title":"Eur J Cancer"},{"issue":"2","key":"2369_CR20","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s10637-021-01191-6","volume":"40","author":"A Nishimura","year":"2022","unstructured":"Nishimura\u00a0A et\u00a0al (2022) Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer. Invest New Drugs 40(2):403\u2013410","journal-title":"Invest New Drugs"},{"issue":"1","key":"2369_CR21","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s00408-022-00511-8","volume":"200","author":"V Avrillon","year":"2022","unstructured":"Avrillon\u00a0V et\u00a0al (2022) Nationwide real-life safety and treatment exposure data on durvalumab after concurrent chemoradiotherapy in unresectable stage\u00a0III, locally advanced, non-small cell lung cancer: analysis of patients enrolled in the French Early Access Program. Lung 200(1):95\u2013105","journal-title":"Lung"},{"key":"2369_CR22","doi-asserted-by":"crossref","unstructured":"Brahmer JR et\u00a0al (2021) Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J\u00a0Immunother Cancer 9(6)","DOI":"10.1136\/jitc-2021-002435"},{"issue":"4","key":"2369_CR23","doi-asserted-by":"publisher","first-page":"482","DOI":"10.2478\/raon-2021-0044","volume":"55","author":"M Vrankar","year":"2021","unstructured":"Vrankar\u00a0M et\u00a0al (2021) Clinical outcomes in stage\u00a0III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapy-single institute experience. Radiol Oncol 55(4):482\u2013490","journal-title":"Radiol Oncol"},{"issue":"1","key":"2369_CR24","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.cllc.2021.08.006","volume":"23","author":"JN LeClair","year":"2022","unstructured":"LeClair\u00a0JN et\u00a0al (2022) Real-world incidence of pneumonitis in patients receiving durvalumab. Clin Lung Cancer 23(1):34\u201342","journal-title":"Clin Lung Cancer"},{"key":"2369_CR25","first-page":"86","volume":"161","author":"G Saito","year":"2021","unstructured":"Saito\u00a0G et\u00a0al (2021) Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005\/CRIMSON). Cancer Treat Res 161:86\u201393","journal-title":"Cancer Treat Res"},{"issue":"9","key":"2369_CR26","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1001\/jamaoncol.2019.1022","volume":"5","author":"A Simonaggio","year":"2019","unstructured":"Simonaggio\u00a0A et\u00a0al (2019) Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer. JAMA Oncol 5(9):1310\u20131317","journal-title":"JAMA Oncol"},{"issue":"3 Suppl)","key":"2369_CR27","doi-asserted-by":"publisher","first-page":"S70","DOI":"10.1016\/j.ijrobp.2009.06.091","volume":"76","author":"LB Marks","year":"2010","unstructured":"Marks\u00a0LB et\u00a0al (2010) Radiation dose-volume effects in the lung. Int J Radiat Oncol Biol Phys 76(3 Suppl)):S70\u2013S76","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"2369_CR28","doi-asserted-by":"publisher","first-page":"237","DOI":"10.5306\/wjco.v13.i4.237","volume":"13","author":"N Rodriguez De Dios","year":"2022","unstructured":"Rodriguez De Dios\u00a0N et\u00a0al (2022) GOECP\/SEOR radiotheraphy guidelines for non-small-cell lung cancer. World J Clin Oncol 13(4):237\u2013266","journal-title":"World J Clin Oncol"},{"key":"2369_CR29","doi-asserted-by":"crossref","unstructured":"Rastmanesh R et\u00a0al (2023) Anti(angiogenic) food components: can be a\u00a0major source of bias in the investigation of angiogenesis inhibi. Ann Transl Med","DOI":"10.21037\/atm-23-1517"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-025-02369-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-025-02369-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-025-02369-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T13:46:49Z","timestamp":1748440009000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-025-02369-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["2369"],"URL":"https:\/\/doi.org\/10.1007\/s00066-025-02369-0","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"type":"print","value":"0179-7158"},{"type":"electronic","value":"1439-099X"}],"subject":[],"published":{"date-parts":[[2025,2,13]]},"assertion":[{"value":"6 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"F.\u00a0Schragel declares that he received honoraria from Roche, Menarini and MSD. K.\u00a0Hackner declares that he received honoraria from AstraZeneca, Roche, Amgen, Novartis, Boehringer Ingelheim, and Excentia and had consulting or advisory roles for Amgen, Novartis, and Boehringer Ingelheim. M.\u00a0Matousek, C.\u00a0Resl, G.\u00a0Kreye, N.-S.\u00a0Le, P.\u00a0Errhalt and P.\u00a0Georg declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Institutional Review Board and the Ethics Committee of Lower Austria (GS4-EK-4\/798-2022) and was conducted according to the Declaration of Helsinki. Patient consent was waived due to the retrospective nature of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}